Erythropoietin (EPO) in acute kidney injury

Annals of Intensive Care

Volumn 1, Issue 1, 2011, Pages 1-10

  Moore, Elizabeth ^a   Bellomo, Rinaldo ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMYLATED EPO; CISPLATIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GENISTEIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; DRUG MECHANISM; ERYTHROPOIESIS; HUMAN; HYPERTENSION; KIDNEY ISCHEMIA; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PURE RED CELL ANEMIA; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; TUMOR GROWTH;

EID: 84855400828     PISSN: None     EISSN: 21105820     Source Type: Journal    
DOI: 10.1186/2110-5820-1-3     Document Type: Review

References (59)

1. Mocini D, Leone T, Tubaro M, Santini M, Penco M: Structure, production and function of erythropoietin: implications for therapeutical use in Cardiovascular disease. Curr Med Chem 2007, 14:2278-87.
2. Boissel JP, Lee WR, Presnell SR, Cohen FE, Bunn HF: Erythropoietin structure-function relationships. Mutant proteins that test a model of tertiary structure. J Biol Chem 1993, 268:15983-93.
3. Catlin DH, Breidbach A, Elliott S, Glaspy J: Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem 2002, 48:2057-9.
4. Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, et al: Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol 2004, 32:1146-55.
5. Rush RS, Derby PL, Smith DM, Merry C, Rogers G, Rohde MF, et al: Microheterogeneity of erythropoietin carbohydrate structure. Anal Chem 1995, 67:1442-52.
6. Rush RS, Derby PL, Strickland TW, Rohde MF: Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis. Anal Chem 1993, 65:1834-42.
7. Middleton SA, Barbone FP, Johnson DL, Thurmond RL, You Y, McMahon FJ, et al: Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide. J Biol Chem 1999, 274:14163-9.
8. Weidemann A, Johnson RS: Nonrenal regulation of EPO synthesis. Kidney Int 2009, 75:682-8.
9. Jelkmann W: Erythropoietin after a century of research: younger than ever. Eur J Haematol 2007, 78:183-205.
10. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB: Beyond anemia: the clinical impact of the physiologic effects of erythropoietin. Semin Dial 2008, 21:447-54.
11. Bahlmann FH, Fliser D: Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens 2009, 18:15-20.
12. Johnson DW, Forman C, Vesey DA: Novel renoprotective actions of erythropoietin: new uses for an old hormone. Nephrology 2006, 11:306-12.
13. Percy MJ, Lee FS, Percy MJ, Lee FS: Familial erythrocytosis: molecular links to red blood cell control. Haematologica 2008, 93:963-7.
14. Li F, Chong ZZ, Maiese K: Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 2004, 13:265-89.
15. Rusai K, Prokai A, Szebeni B, Fekete A, Treszl A, Vannay A, et al: Role of serum and glucocorticoid-regulated kinase-1 in the protective effects of erythropoietin during renal ischemia/reperfusion injury. Biochem Pharmacol 2010, 79:1173-81.
16. Myklebust JH, Smeland EB, Josefsen D, Sioud M: Protein kinase C-alpha isoform is involved in erythropoietin-induced erythroid differentiation of CD34(+) progenitor cells from human bone marrow. Blood 2000, 95:510-8.
17. Miller BA, Barber DL, Bell LL, Beattie BK, Zhang MY, Neel BG, et al: Identification of the erythropoietin receptor domain required for calcium channel activation. J Biol Chem 1999, 274:20465-72.
18. Figueroa YG, Chan AK, Ibrahim R, Tang Y, Burow ME, Alam J, et al: NF-kappaB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Exp Hematol 2002, 30:1419-27.
19. Yang CW, Li C, Jung JY, Shin SJ, Choi BS, Lim SW, et al: Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 2003, 17:1754-5.
20. Lui JC, Kong SK, Lui JC-K, Kong S-K: Heat shock protein 70 inhibits the nuclear import of apoptosis-inducing factor to avoid DNA fragmentation in TF-1 cells during erythropoiesis. FEBS Lett 2007, 581:109-17.
21. Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, et al: Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nature Cell Biology 2000, 2:469-75.
22. Elliott S, Pham E, Macdougall IC, Elliott S, Pham E, Macdougall IC: Erythropoietins: a common mechanism of action. Exp Hematol 2008, 36:1573-84.
23. Salahudeen AK, Haider N, Jenkins J, Joshi M, Patel H, Huang H, et al: Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol 2008, 294:F1354-65.
24. Silva M, Benito A, Sanz C, Prosper F, Ekhterae D, Nunez G, et al: Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 1999, 274:22165-9.
25. Chatterjee PK: Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 2007, 376:1-43.
26. Joyeux-Faure M, Godin-Ribuot D, Ribuot C: Erythropoietin and myocardial protection: what's new? Fundam Clin Pharmacol 2005, 19:439-46.
27. Westenfelder C, Biddle DL, Baranowski RL: Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999, 55:808-20.
28. Ates E, Yalcin AU, Yilmaz S, Koken T, Tokyol C, Ates E, et al: Protective effect of erythropoietin on renal ischemia and reperfusion injury. ANZ J Surg 2005, 75:1100-5.
29. Esposito C, Pertile E, Grosjean F, Castoldi F, Diliberto R, Serpieri N, et al: The improvement of ischemia/reperfusion injury by erythropoietin is not mediated through bone marrow cell recruitment in rats. Transplant Proc 2009, 41:1113-5.
30. Forman CJ, Johnson DW, Nicol DL: Erythropoietin administration protects against functional impairment and cell death after ischaemic renal injury in pigs. BJU Int 2007, 99:162-5.
31. Gong H, Wang W, Kwon T-H, Jonassen T, Li C, Ring T, et al: EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int 2004, 66:683-95.
32. Imamura R, Moriyama T, Isaka Y, Namba Y, Ichimaru N, Takahara S, et al: Erythropoietin protects the kidneys against ischemia reperfusion injury by activating hypoxia inducible factor-1alpha. Transplantation 2007, 83:1371-9.
33. Imamura R, Okumi M, Isaka Y, Ichimaru N, Moriyama T, Imai E, et al: Carbamylated erythropoietin improves angiogenesis and protects the kidneys from ischemia-reperfusion injury. Cell Transplant 2008, 17:135-41.
34. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC: Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006, 69:1806-13.
35. Kiris I, Kapan S, Kilbas A, Yilmaz N, Altuntas I, Karahan N, et al: The protective effect of erythropoietin on renal injury induced by abdominal aortic-ischemia-reperfusion in rats. J Surg Res 2008, 149:206-13.
36. Nemoto T, Yokota N, Keane WF, Rabb H: Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int 2001, 59:246-51.
37. Patel NSA, Sharples EJ, Cuzzocrea S, Chatterjee PK, Britti D, Yaqoob MM, et al: Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 2004, 66:983-9.
38. Phillips CK, Hruby GW, Mirabile G, Motamedinia P, Lehman DS, Okhunov Z, et al: Erythropoietin-induced optimization of renal function after warm ischemia. J Endourol 2009, 23:359-65.
39. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, et al: Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004, 15:2115-24.
40. Spandou E, Tsouchnikas I, Karkavelas G, Dounousi E, Simeonidou C, Guiba-Tziampiri O, et al: Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant 2006, 21:330-6.
41. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW: Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004, 19:348-55.
42. Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NSA, Yaqoob MM, et al: Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004, 22:63-9.
43. Andreucci M, Fuiano G, Presta P, Lucisano G, Leone F, Fuiano L, et al: Downregulation of cell survival signalling pathways and increased cell damage in hydrogen peroxide-treated human renal proximal tubular cells by alpha-erythropoietin. Cell Prolif 2009, 42:554-61.
44. Bagnis C, Beaufils H, Jacquiaud C, Adabra Y, Jouanneau C, Le Nahour G, et al: Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 2001, 16:932-8.
45. Bi B, Guo J, Marlier A, Lin SR, Cantley LG: Erythropoietin expands a stromal cell population that can mediate renoprotection. Am J Physiol Renal Physiol 2008, 295:F1017-22.
46. Fishbane S, Ragolia L, Palaia T, Johnson B, Elzein H, Maesaka JK, et al: Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells. Kidney Int 2004, 65:452-8.
47. Goldfarb M, Rosenberger C, Ahuva S, Rosen S, Heyman SN: A role for erythropoietin in the attenuation of radiocontrast-induced acute renal failure in rats. Ren Fail 2006, 28:345-50.
48. Hamano Y, Aoki T, Shirai R, Hatano M, Kimura R, Ogawa M, et al: Low-dose darbepoetin alpha attenuates progression of a mouse model of aristolochic acid nephropathy through early tubular protection. Nephron Experimental Nephrology 2010, 114:e69-81.
49. Kang D-H, Park E-Y, Yu ES, Lee Y-S, Yoon K-I: Renoprotective effect of erythropoietin (EPO): possibly via an amelioration of renal hypoxia with stimulation of angiogenesis in the kidney. Kidney Int 2005, 67:1683.
50. Mitra A, Bansal S, Wang W, Falk S, Zolty E, Schrier RW: Erythropoietin ameliorates renal dysfunction during endotoxemia. Nephrol Dial Transplant 2007, 22:2349-53.
51. Nijboer WN, Ottens PJ, van Dijk A, van Goor H, Ploeg RJ, Leuvenink HGD: Donor pretreatment with carbamylated erythropoietin in a brain death model reduces inflammation more effectively than erythropoietin while preserving renal function. Crit Care Med 2010, 38:1155-61.
52. Vaziri ND, Zhou XJ, Liao SY: Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 1994, 266:F360-6.
53. Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Ishii N, et al: Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007, 100:662-669.
54. Bagshaw SM, George C, Dinu I, Bellomo R: A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008, 23:1203-10.
55. Ostermann M, Chang RWS: Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007, 35:1837-43.
56. Song YR, Lee T, You SJ, Chin HJ, Chae D-W, Lim C, et al: Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol 2009, 30:253-60.
57. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, et al: Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010, 77:1020-30.
58. McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, et al: Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008, 48:1754-62.
59. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009, 373:1532-42.